We have located links that may give you full text access.
Journal Article
Review
Omalizumab for asthma: indications, off-label uses and future directions.
Recent Patents on Inflammation & Allergy Drug Discovery 2010 November
Omalizumab is a recombinant humanized monoclonal antibody. Use of omalizumab is reported to benefit significantly a subset of asthmatics patients with inadequately controlled moderate-to-severe persistent allergic asthma that is not controlled with high-dose inhaled corticosteroids. However, recent reports and patents suggest wider applications in asthma and related diseases. In this review unmet needs and future directions regarding the use of omalizumab in asthma are discussed. Better understanding of omalizumab's mechanisms of action on one hand and asthma and related pathogenesis on the other hand might contribute to the development of better future guidelines of omalizumab use in asthma patients.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app